Broad AD/PD 2026 Validation Reinforces ALZpath pTau217 Antibody as Industry Benchmark for Blood-Based Alzheimer’s Diagnosis

ALZpath, Inc., a leader in blood test-based diagnostic solutions for Alzheimer’s disease, announced the use of its proprietary pTau217 antibody across 29 presentations at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD). The wide adoption of the antibody demonstrates its high diagnostic accuracy and disease specificity, highlighting the emergence of pTau217 as a leading blood‑based biomarker for Alzheimer’s disease and reinforcing its position as the preferred pTau217 antibody for scalable, high-performance testing worldwide.

ALZpath’s pTau217 antibody is a validated and foundational component of globally accessible diagnostic solutions, selected by leading in-vitro diagnostic (IVD) companies as the basis for the development of blood-based assays. Its platform-agnostic design enables seamless integration across diverse laboratory infrastructures.

"Our collaboration with a robust ecosystem of assay developers and clinical providers aims to streamline the transition of pTau217 testing into routine medical practice to help address the projected 152 million global cases of dementia among adults aged 65+ by 2050,” said Mike Banville, CEO of ALZpath. "The demonstration of ongoing innovation in assay sensitivity and specificity in pTau217 specifically promises earlier detection, more accurate staging, and better monitoring of therapeutic responses, which is vital in the evolving diagnostic landscape for Alzheimer’s disease."